ImmunoPrecise Antibodies (IPA) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
ImmunoPrecise Antibodies has secured a financing deal with Yorkville Advisors for up to $3 million in convertible debentures, aimed at bolstering the company’s capital. The agreement includes two tranches, with the first already completed and the second contingent on SEC regulatory approval. These debentures can be converted into common shares, subject to terms including interest rates and potential redemption premiums.
For further insights into IPA stock, check out TipRanks’ Stock Analysis page.